Eris Lifesciences Limited
Eris Lifesciences Limited Fundamental Analysis
Eris Lifesciences Limited (ERIS.NS) shows moderate financial fundamentals with a PE ratio of 43.55, profit margin of 14.09%, and ROE of 13.93%. The company generates $30.6B in annual revenue with strong year-over-year growth of 44.59%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 61.3/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze ERIS.NS's fundamental strength across five key dimensions:
Efficiency Score
WeakERIS.NS struggles to generate sufficient returns from assets.
Valuation Score
WeakERIS.NS trades at a premium to fair value.
Growth Score
ModerateERIS.NS shows steady but slowing expansion.
Financial Health Score
ModerateERIS.NS shows balanced financial health with some risks.
Profitability Score
WeakERIS.NS struggles to sustain strong margins.
Key Financial Metrics
Is ERIS.NS Expensive or Cheap?
P/E Ratio
ERIS.NS trades at 43.55 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, ERIS.NS's PEG of 11.36 indicates potential overvaluation.
Price to Book
The market values Eris Lifesciences Limited at 6.08 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 15.11 times EBITDA. This signals the market has high growth expectations.
How Well Does ERIS.NS Make Money?
Net Profit Margin
For every $100 in sales, Eris Lifesciences Limited keeps $14.09 as profit after all expenses.
Operating Margin
Core operations generate 34.17 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $13.93 in profit for every $100 of shareholder equity.
ROA
Eris Lifesciences Limited generates $6.03 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Eris Lifesciences Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Eris Lifesciences Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
ERIS.NS converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
43.55
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
11.36
vs 25 benchmark
P/B Ratio
Price to book value ratio
6.08
vs 25 benchmark
P/S Ratio
Price to sales ratio
6.13
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.77
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.91
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.14
vs 25 benchmark
ROA
Return on assets percentage
0.06
vs 25 benchmark
ROCE
Return on capital employed
0.19
vs 25 benchmark
How ERIS.NS Stacks Against Its Sector Peers
| Metric | ERIS.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 43.55 | 29.45 | Worse (Expensive) |
| ROE | 13.93% | 779.00% | Weak |
| Net Margin | 14.09% | -24936.00% (disorted) | Strong |
| Debt/Equity | 0.77 | 0.26 | Weak (High Leverage) |
| Current Ratio | 0.91 | 4.65 | Weak Liquidity |
| ROA | 6.03% | -19344.00% (disorted) | Weak |
ERIS.NS outperforms its industry in 1 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Eris Lifesciences Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
173.83%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
19.42%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
295.33%
Industry Style: Defensive, Growth, Innovation
High Growth